Suzhou Zelgen Biopharmaceuticals Co Ltd (688266 SHG) stock market data APIs
¥88.892
0.44(0.5%)
as of November 11, 2026
Try our APIs with
free plan!
Suzhou Zelgen Biopharmaceuticals Co Ltd Financial Data Overview
Price chart is built with
Anychart
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for hemostasis. It also develops gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, and myelofibrosis; recombinant human thyroid-stimulating hormone for injection; and ZG006 for injection, indications for small cell lung cancer, neuroendocrine carcinoma, and other advanced tumors. In addition, it develops ZG005 for injection, which is in phase I/II clinical trial for cervical cancer, liver cancer, neuroendocrine carcinoma and other advanced tumors; and ZGGS18, ZGGS15, ZGGS34, ZG016, ZG2273, ZG2001film, and ZG0895 hydrochloric acid for injection indications for advance tumors. The company's products are used in multiple therapeutic areas, such as tumors and hematological diseases, bleeding and trauma, and immune inflammatory diseases. Suzhou Zelgen Biopharmaceuticals Co., Ltd. was founded in 2009 and is based in Kunshan, the People's Republic of China.
Prev. Close
88.892
Open
89.3316
High
89.3316
Low
85.1666
52 wk Range
75.1-160
Market Cap
23 416 M
P/E Ratio
41.3364
Shares Outstanding
265 M
Revenue
1 754 M
EPS
-0.39
Beta
-0.113
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Suzhou Zelgen Biopharmaceuticals Co Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Suzhou Zelgen Biopharmaceuticals Co Ltd data using free add-ons & libraries
Get Suzhou Zelgen Biopharmaceuticals Co Ltd Fundamental Data
Suzhou Zelgen Biopharmaceuticals Co Ltd Fundamental data includes:
- Net Revenue: 1 754 M
- EBITDA: 532 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Suzhou Zelgen Biopharmaceuticals Co Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2023-04-21
- EPS/Forecast: NaN
Get Suzhou Zelgen Biopharmaceuticals Co Ltd End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Suzhou Zelgen Biopharmaceuticals Co Ltd News
New
3 Asian Stocks Estimated To Be Undervalued By Up To 49.6%
As global markets experience mixed performances, with Japan's stock markets declining and China's manufacturing sector showing modest improvement, investors are increasingly turning their attention to...
Asian Market Value Stock Picks Featuring WuXi XDC Cayman And Two More
As the Asian markets navigate a complex landscape marked by mixed performances and cautious economic optimism, investors are increasingly on the lookout for opportunities in undervalued stocks. In thi...
111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China
SHANGHAI, Aug. 3, 2021 /PRNewswire/ – 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and...
Get Suzhou Zelgen Biopharmaceuticals Co Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.